Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30502812 | 0.92 | ALDH1A1 (0.54) | ALDH1A1LMNAPKMMEN1KMT2A | |
| SCHEMBL2519991 | 0.92 | ALDH1A1 (0.54) | ALDH1A1LMNAPKMMEN1KMT2A | |
| SCHEMBL25433999 | 0.91 | ALDH1A1 (0.53) | ALDH1A1LMNAPKMMEN1KMT2A | |
| SCHEMBL25434818 | 0.90 | ALDH1A1 (0.50) | ALDH1A1LMNAPKMMEN1KMT2A | |
| SCHEMBL30502819 | 0.88 | PKM (0.47) | ALDH1A1LMNAPKMMEN1KMT2A | |
| SCHEMBL2520783 | 0.88 | PKM (0.47) | ALDH1A1LMNAPKMMEN1KMT2A | |
| SCHEMBL31217219 | 0.88 | ALDH1A1 (0.47) | ALDH1A1LMNAPKMMEN1KMT2A | |
| SCHEMBL30502815 | 0.88 | PKM (0.47) | ALDH1A1LMNAPKMMEN1KMT2A | |
| SCHEMBL25433441 | 0.84 | ALDH1A1 (0.54) | ALDH1A1LMNAPKMMEN1KMT2A | |
| SCHEMBL25434397 | 0.83 | ALDH1A1 (0.56) | ALDH1A1LMNAPKMMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912723-B2 | KRAS modulators and uses thereof | QUANTA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230374042-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374042-A1 | KRAS MODULATORS AND USES THEREOF | KRAS, NRAS, HRAS | ALDH1A1 3733/4885LMNA 4214/4885PKM 2837/4885 |
| US-11912723-B2 | KRAS modulators and uses thereof | KRAS, NRAS, HRAS | ALDH1A1 3733/4885LMNA 4214/4885PKM 2837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.